How Often Do SSRIs and Other New-Generation Antidepressants Lose Their Effect During Continuation Treatment?: Evidence Suggesting the Rate of True Tachyphylaxis During Continuation Treatment Is Low
The DOI matches its Crossref record.
Abstract
OBJECTIVE: A substantial number of patients who respond to antidepressants experience a relapse despite ongoing pharmacotherapy. The return of symptoms has been interpreted as a loss of the effectiveness of antidepressant activity. However, patients who initially improve while taking antidepressants include an admixture of true drug responders and placebo responders. Consequently, symptom return despite ongoing treatment may not represent a loss of drug effect because the patient may not have experienced a true drug response in the first place. The goal of the present report is to estimate the proportion of relapse attributable to the loss of true drug response versus a loss of placebo response. DATA SOURCES: We reviewed continuation studies of new-generation antidepressants that began as placebo-controlled acute-phase studies. Studies were identified using MEDLINE (English-language articles published from 1980 to 2005 in 23 prespecified journals, using the search terms depression, continuation, and tachyphylaxis). Finally, we identified studies in reference lists of pertinent studies and review articles. STUDY SELECTION: Five studies were reviewed and selected according to the following criteria: continuation studies of new-generation antidepressants that began as placebo-controlled acute-phase studies. One of the studies was excluded from our analyses because it did not report response rates in the acute phase, and we could not find acute-phase response rates in related reports. DATA SYNTHESIS: Using the 2 formulas proposed by Quitkin and colleagues, we estimated the proportion of relapse attributable to the loss of true drug response versus the loss of response attributable to the nonspecific effects of treatment: The relapse rate in placebo responders was 24.1%, whereas the relapse rate in antidepressant responders was 7.4%. Two different methods of estimating relapse suggested that the majority of relapses in patients taking antidepressants during continuation treatment could be attributed to relapses occurring in patients who were not true drug responders. CONCLUSION: Most of the relapse rate during new-generation antidepressant continuation treatment may be due to relapse in patients who were not true drug responders, which suggests that loss of true drug response may be less common than previously thought.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the true rates of tachyphylaxis occurring during continuation treatment with drugs for depression for MDD may be lower than once thought [19]”
Citations
Cites
Still being checked.
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
Morbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
The Mistreatment of Major Depressive Disorder
Paris, J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900306 · Cited by 60
Depression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 56
Time to Relapse After Short- or Long-term Treatment of Severe Premenstrual Syndrome With Sertraline
Freeman, E. W., Rickels, K., Sammel, M. D., Lin, H., & Sondheimer, S. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.547 · Cited by 51
Guidelines for the diagnosis and treatment of depressive disorders in China: The second edition
Feng, Y., Xiao, L., Wang, W., Ungvari, G. S., Ng, C. H., Wang, G., & Xiang, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.104 · Cited by 51
Therapeutic management of premenstrual syndrome
Freeman, E. W. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.509344 · Cited by 46
Hamoda, H. M., & Osser, D. N. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802277904 · Cited by 47
Tachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Zajecka, J., D, M. F. M., Shelton, R. C., Barrentine, L. W., Young, P., & Papakostas, G. I. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10181 · Cited by 30
Cleveland, W. L., DeLaPaz, R. L., Fawwaz, R. A., & Challop, R. S. (2009) · Neural Plasticity · doi:10.1155/2009/768398 · Cited by 28
Giakoumatos, C. I., & Osser, D. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27
Amsterdam, J. D., & Shults, J. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.07.007 · Cited by 29
Johnson, C. F. A., Dougall, N. J., Williams, B., MacGillivray, S. A., Buchanan, A. I., & Hassett, R. (2014) · BMC Family Practice · doi:10.1186/s12875-014-0210-9 · Cited by 25
Tachyphylaxis/ tolerance to antidepressive medications: a review.
Katz, G. (2011) · PubMed · Cited by 23
Amsterdam, J. D., Lorenzo‐Luaces, L., & DeRubeis, R. J. (2016) · Bipolar Disorders · doi:10.1111/bdi.12442 · Cited by 18
Amsterdam, J. D., & Kim, T. T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001049 · Cited by 17
Seabrooke, S., & O’Donnell, M. J. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00408.2012 · Cited by 18
Xiao, C., Zhou, J. L., Li, A., Zhang, L., Zhu, X., Zhou, J., Hu, Y., Zheng, Y., Liu, J., Deng, Q., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28817 · Cited by 14
Katz, G. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02231.x · Cited by 12
Moraga‐Amaro, R., Guerrin, C. G. J., Nazario, L. R., Giacobbo, B. L., Dierckx, R., Stehberg, J., de Vries, E. F. J., & Doorduin, J. (2022) · Stress · doi:10.1080/10253890.2022.2045269 · Cited by 9
Hunter, A. M., Cook, I. A., Abrams, M., & Leuchter, A. F. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.016 · Cited by 10
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 3
Evidence of new-onset depression among persons with migraine after discontinuing antidepressants
Kious, B. M., & Bakian, A. V. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112990 · Cited by 1
BOLAND, R. J., Gaud, K. G., & Keller, M. B. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch103 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Santone, G., Bellantuono, C., & Psichiatrica, C. (2009) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology
Laux, G. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_67-1 · Cited by 1
Metadata
- Authors
- Zimmerman, M., & Thongy, T.
- Affiliations
- Brown University (US)
- ORCID
- Zimmerman, Mark
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-08-15
- Volume
- 68
- Issue
- 08
- Pages
- 1271-1276
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2084249661
- Cited by
- 31
- References
- 0
- Citations by year
- 2023: 1 · 2022: 1 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- selective serotonin reuptake inhibitors, continuation treatment, placebo responders, drug response, tachyphylaxis, depression
- MeSH terms
- Antidepressive Agents, Depression, Drug Administration Schedule, Humans, Research Design, Tachyphylaxis, Placebo Effect, Selective Serotonin Reuptake Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.